ChartMill · Sep 7, 2026
Curious about the stocks that are showing activity after the closing bell on Monday?
Discover the top movers in Monday's after-hours session and stay informed about the post-market dynamics.
NASDAQ · BTAI
BioXcel Therapeutics, Inc.
Healthcare · Biotechnology
$0.07
Up+$0.00 (+0.00%)
Updated Sep 11, 2026, 2:14 AM
SID Score
3.5/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 45.49M
- P/E ratio
- -0.32
- Dividend yield
- 0.00%
- 52-week range
- $0.07 – $4.29
- Volume
- 47.48M
- Avg. volume
- 961.53K
Price performance
BTAI price history
1M range · 17 trading sessions · Daily adjusted prices
BTAI closed at $0.07 after 17 trading sessions, down 93.46% for the selected period.
- Last close
- $0.07
- Period change
- -93.46%
- Period low
- $0.07
- Period high
- $1.19
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 4, 2026 | $0.0927 | $0.0935 | $0.069 | $0.0739 | 47.48M |
| Sep 3, 2026 | $0.1201 | $0.1272 | $0.11 | $0.1175 | 151M |
| Sep 2, 2026 | $0.13 | $0.197 | $0.1055 | $0.107 | 46.79M |
| Sep 1, 2026 | $0.14 | $0.1416 | $0.12 | $0.137 | 15.69M |
| Aug 31, 2026 | $0.1509 | $0.17 | $0.1415 | $0.1628 | 10.78M |
| Aug 28, 2026 | $0.224 | $0.2299 | $0.1569 | $0.1814 | 58.56M |
| Aug 27, 2026 | $0.7492 | $0.7632 | $0.7001 | $0.7188 | 1.08M |
| Aug 26, 2026 | $0.758 | $0.7853 | $0.7364 | $0.78 | 902.2K |
| Aug 25, 2026 | $0.7829 | $0.8113 | $0.711 | $0.7422 | 1.58M |
| Aug 24, 2026 | $0.80 | $0.833 | $0.751 | $0.7606 | 1.12M |
| Aug 21, 2026 | $0.81 | $0.859 | $0.792 | $0.8038 | 1.24M |
| Aug 20, 2026 | $0.84 | $0.84 | $0.7979 | $0.7985 | 902.32K |
| Aug 19, 2026 | $0.79 | $0.8637 | $0.79 | $0.8274 | 797.61K |
| Aug 18, 2026 | $0.85 | $0.8955 | $0.7801 | $0.7921 | 1.85M |
| Aug 17, 2026 | $1.03 | $1.03 | $0.85 | $0.89 | 2.2M |
| Aug 14, 2026 | $1.11 | $1.24 | $1.015 | $1.19 | 2.03M |
| Aug 13, 2026 | $1.10 | $1.16 | $1.05 | $1.13 | 1.09M |
Latest BTAI news
The latest Smart Investors Daily articles mentioning BTAI.
Stock researchCompany · Overview
BTAI research
Overview
Company profile and research snapshot.
Company profile
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- Buy
- Average target
- $12.00
- Implied upside
- —
- Analysts
- 11
| Date | Firm | Rating | Target |
|---|---|---|---|
| Apr 2, 2026 | HC Wainwright & Co. | Buy | — |
| Mar 17, 2026 | Rodman & Renshaw | Buy | — |
| Mar 5, 2026 | HC Wainwright & Co. | Buy | — |
| Sep 15, 2025 | HC Wainwright & Co. | Buy | — |
| Sep 12, 2025 | Mizuho | Neutral | — |
News briefing
No generated briefing is available yet.
ChartMill · Sep 4, 2026
Which stocks are experiencing notable movement on Friday?
Let's have a look at what is happening on the US markets one hour before the close of the markets on Friday. Below you can find the top gainers and losers in today's session.
Benzinga · Sep 4, 2026
12 Health Care Stocks Moving In Friday's After-Market Session
Gainers iSpecimen (NASDAQ:ISPC) shares increased by 10.4% to $1.7 during Friday's after-market session. The market value of their outstanding shares is at $3.8 million. Genelux (NASDAQ:GNLX) stock moved upwards by
ChartMill · Sep 4, 2026
The trading volume of these stocks is deviating from the norm in today's session.
Unusual volume stocks are being observed in Friday's session.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
